Molecularly-targeted therapies for non-small cell lung cancer

Bibliography

• DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl. J. Med. (2001) 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl. J. Med. (2002) 347:472–480.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl. J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• JEMAL A, TIWARI RC, MURRAY T et al.: Cancer statistics, 2004. CA Cancer]. Clin. (2004) 54:8–29.
   PubMed Web of Science ®Google Scholar
• RAMALINGAM S, BELANI CP: State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin. Oncol (2004) 31:68–74.
   PubMed Web of Science ®Google Scholar
• ARRIAGADA R, BERGMAN B, DUNANT A. LE CHEVALIER T, PIGNON JP, VANSTEENKISTE J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl. J. Med. (2004) 350:351–360.
   Google Scholar
• •This large randomised trial demonstrated a 4.1% absolute improvement in 5-year survival with adjuvant chemotherapy for patients with resected early stage non-small cell lung cancer.
   Google Scholar
• WINTON TL, LIVINGSTON R, JOHNSON D et al.: A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstr. 7018.
   Google Scholar
• •This study confirmed the benefit of adjuvant chemotherapy for patients with early stage non-small cell lung cancer.
   Google Scholar
• STRAUSS GM, HERNDON J, MADDAUS MA, JOHNSTONE DW, JOHNSON EA, WATSON DM: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage TB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc. Am. Soc. Clin. Oncol (2004) 23:Abstr. 7019.
   Google Scholar
• •This study established the efficacy of carboplatin/paditaxel regimen for patients with Stage TB non-small cell lung cancer following surgical resection.
   Google Scholar
• RAMALINGAM S, BELANI CP: Results of clinical trials for locally advanced and metastatic non small-cell lung cancer. Semin. Thorac. Cardiovasc. Surg. (2003) 15:438–447.
   PubMedGoogle Scholar
• SCHILLER J: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. J. Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• •Landmark trial that demonstrated comparable efficacy for four different platinum-based regimens in advanced non-small cell lung cancer.
   Google Scholar
• LANGER C, STEPHENSON P, SCHILLER J, TESTER WJ, RAPOPORT BL: ECOG 1599: Randomized Phase II study of paclitaxel/ carboplatin versus cisplatin/gemcitabine in performance status (PS) W patients with treatment-naive advanced NSCLC. Lung Cancer (2003) 41:S18.
   Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol (2000) 18:2095–2103.
   PubMed Web of Science ®Google Scholar
• •This study established the role for second-line chemotherapy with docetaxel for patients with advanced non-small cell lung cancer.
   Google Scholar
• HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Clin. Oncol (2004) 22:1589–1597.
   Web of Science ®Google Scholar
• •This Phase III study led to the approval of pemetrexed for second line therapy of advanced non-small cell lung cancer.
   Google Scholar
• BASELGA J, ALBANELL J: Targeting epidermal growth factor receptor in lung cancer. Curr. Oncol Rep. (2002) 4:317–324.
   PubMedGoogle Scholar
• BASELGA J: The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer (2001) 37 (Suppl. 4):516–522.
   Google Scholar
• LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl. J. Med. (2004) 350:2129–2139.
   PubMed Web of Science ®Google Scholar
• •First report of epidermal growth factor receptor mutations in non-small cell lung cancer.
   Google Scholar
• HUANG SM, HARARI PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs (1999) 17:259–269.
   PubMed Web of Science ®Google Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol (2002) 20:110–124.
   PubMed Web of Science ®Google Scholar
• BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol (2002) 20:4292–4302.
   PubMed Web of Science ®Google Scholar
• FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol (2003) 21:2237–2246.
   PubMed Web of Science ®Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290:2149–2158.
   PubMed Web of Science ®Google Scholar
• •Randomised Phase II study that led to the approval of gefitinib by the FDA for therapy of non-small cell lung cancer.
   Google Scholar
• HOTTA K, HARITA S, BESSHO A, YONEI T, GEMBA K, AOE K: Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group. Proc. Am. Soc. Clin. Oncol (2004) 23:629, Abstr. 7063.
   Google Scholar
• KRIS MG, SANDLER k MILLER V, CESPON M, ZAKOWSKI M, PIZZO B: Cigarette smoking history predicts sensitivity to erlotinib: results of a Phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc. Am. Soc. Clin. Oncol (2004) 23:628, Abstr. 7062.
   Google Scholar
• THATCHER N, CHANG k PARIKH P, PEMBERTON K, ARCHER A: Pr4 ISEL: A Phase III survival study comparing gefitinib plus best supportive care with placebo plus BDC in patients with advanced non-small cell lung cancer who had received one or two prior chemotherapy regimens. Lung Cancer (2005):Abstr. S4.
   Google Scholar
• KELLY K, GASPAR LE, CHANSKY K, ALBAIN KS, CROWLEY J, GANDARA DR: Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing Phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J. Clin. Oncol. (2005) 23\(Suppl. 16):Abstr. 7058.
   Google Scholar
• SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et ah Erlotinib in previously treated non-small-cell lung cancer. N Engl. J. Med. (2005) 353(2):123–132.
   PubMed Web of Science ®Google Scholar
• PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
   Google Scholar
• MILLER VA, KRIS MG, SHAH N et al.: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:1103–1109.
   PubMed Web of Science ®Google Scholar
• WEST H, FRANKLIN WA, GUMERLOCK PH et al.: Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc. Am. Soc. Clin. Oncol (2004) 23:618, Abstr. 7014.
   Google Scholar
• MOHAMED MK, RAIVIALINGAM S, LIN Y, GOODING WE, CRONIN W, ECKARDT J: Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:Abstr. 7097.
   Google Scholar
• JANNE PA, GURUBHAGAVATULA S, YEAP BY et al.: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, `Iressa') on an expanded access study. Lung Cancer (2004) 44:221–230.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol (2001) 19:3267–3279.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol (2004) 22:3238–3247.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, PEREIRA J, CIULEANU TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc. Am. Soc. Clin. Oncol (2004) 23:Abstr. 7022.
   Google Scholar
• •First study to demonstrate survival advantage for non-small cell lung cancer patients treated with an epidermal growth factor receptor inhibitor.
   Google Scholar
• MILLER VA, HERBST R, PRAGER D, FEHRENBACHER L, HERMANN R, HOFFMAN P: Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HC1 (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. Proc. Am. Soc. Clin. Oncol (2004) 23:628, Abstr. 7061.
   Google Scholar
• SIROTNAK FM, ZAKOWSKI MF, MILLER VA, SCHER HI, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885–4892.
   PubMed Web of Science ®Google Scholar
• HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2.1 Clin. Oncol (2004) 22:785–794.
   Google Scholar
• GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT i f. Clin. Oncol (2004) 22:777–784.
   Web of Science ®Google Scholar
• GATZEMEIER U, PLUZANSKA A, SZCZESNA A, KAUKEL E, ROUBEC J, BRENNSCHEIDT U: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:617, Abstr.: 7010.
   Google Scholar
• HERBST RS, PRAGER D, HERMANN R, MILLER V, FEHRENBACHER L, HOFFMAN P: TRIBUTE - a Phase III trial of erlotinib HC1 (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:617, Abstr. 7011.
   Google Scholar
• PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA (2004) 101:13306–13311.
   PubMed Web of Science ®Google Scholar
• HUANG SF, LIU HP, LI LH et al.: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. (2004) 10:8195–8203.
   PubMed Web of Science ®Google Scholar
• TSAO MS, SAKURADA A, LORIMER I, CUTZ JC, KAMEL-REID S, SQUIRE J: Molecular analysis of the epidermal growth factor receptor gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCI-CTG) trial BR.21. J. Clin. Oncol (2005) 23:Abstr. 7007, 622.
   Google Scholar
• HIRSCH FR, GANDARA D, MCCOY J, CROWLEY J, WEST H, GUMERLOCK P: Increased EGFR gene copy number detected by FISH is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (S0126). Clin. Oncol (2005) 23:Abstr. 7030.
   Google Scholar
• GUMERLOCK P, HOLLAND WS, CHEN H, FRANKLIN Wk HIRSCH F, MACK PC: Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) S0126 of bronchioloalveolar carcinoma patients treated with gefitinib. Clin. Oncol (2005) 23:623, Abstr. 7008.
   Google Scholar
• KRIS MG, SANDLER A. MILLER VA, ZAKOWSKI MF, PAO W, TSAO A: EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a Phase II multicenter trial. Clin. Oncol (2005) 23:Abstr. 7029, 627.
   Google Scholar
• LILENBAUM R, BONOMI P, ANSARI R et al.: A Phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. J. Clin. OncoL (2005) 23:Abstr. 7036.
   Google Scholar
• KELLY K, HANNA N, ROSENBERG P et al.: A multi-centered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:644, Abstr. 2592.
   Google Scholar
• ROBERT F, BLUMENSCHEIN G, DICKE K, TSENG J, SALEH N: Phase Ib/ IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2003) 22:643 Abstr. 2587.
   Google Scholar
• ROSELL R, DANIEL C, RAMLAU R, SZCZESNA A. CONSTENLA M, MENNECIER B: Randomized Phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:618, Abstr. 7012.
   Google Scholar
• CRAWFORD J, SANDLER AB, HAMMOND LA et al.: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:634, Abstr. 7083.
   Google Scholar
• BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3:401–410.
   PubMed Web of Science ®Google Scholar
• ESKENS FA: Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br. J. Cancer (2004) 90:1–7.
   Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY Wet al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J. Med. (2004) 350:2335–2342.
   Google Scholar
• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669–676.
   PubMed Web of Science ®Google Scholar
• SANDLER A. GRAY R, BRAHMER J, DOWLATI A, SCHILLER J, PERRY M: Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: An Eastern Cooperative Oncology Group Trial- E4599. J. Clin. Oncol. (2005) 23:Abstr. LBA4, 2.
   Google Scholar
• •Recent study that established survival advantage for bevacizumab in combination with chemotherapy for certain subsets of patients with advanced non-small cell lung cancer.
   Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184–2191.
   PubMed Web of Science ®Google Scholar
• SCHENKEIN DP: Use of proteasome inhibition in the treatment of lung cancer. Clin. Lung Cancer (2004) 6 (Suppl. 2):589–596.
   Google Scholar
• MACK PC, DAVIES AM, LARA PN, GUMERLOCK PH, GANDARA DR: Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer (2003) 41\(Suppl. 1):589–596.
   Google Scholar
• STEVENSON JP, NHO CW, JOHNSON SW, EVANS TL, ALGAZY KA, GALLAGHER M: Effects of bortezomib (PS-341) on NF-KB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: a Phase II/ pharmacodynamic trial. Proc. Am. Soc. Clin. Oncol. (2004) 23:649, Abstr. 7145.
   Google Scholar
• DAVIES AM, LARA PN, LAU DH, MACK PC, GUMERLOCK PH, GANDARA DR: The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a Phase I California Cancer Consortium study. Proc. Am. Soc. Clin. Oncol. (2004) 23:639, Abstr. 7106.
   Google Scholar
• AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8:2505–2511.
   PubMed Web of Science ®Google Scholar
• DAVIES H, BIGNELL GR, COX C et aL:Mutations of the BRAF gene in human cancer. Nature (2002) 417:949–954.
   PubMed Web of Science ®Google Scholar
• STRUMBERG D, RICHLY H, HILGER RA et al.: Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor bay 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. (2004).
   Google Scholar
• SPORN MB, ROBERTS AB: Role of retinoids in differentiation and carcinogenesis. j NatL Cancer Inst. (1984) 73:1381–1387.
   PubMedGoogle Scholar
• KIM ES, HONG WK, KHURI FR: Prevention of lung cancer. The new millennium. Chest Surg. Clin. N Am. (2000) 10:663–690.
   PubMedGoogle Scholar
• KHURI FR, LOTAN R, KEMP BL et aL:Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J. Clin. Oncol. (2000) 18:2798–2804.
   PubMed Web of Science ®Google Scholar
• SONG JI, LANGO MN, HWANG JD et al.: Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. (2001) 61:5919–5925.
   PubMed Web of Science ®Google Scholar
• MANGELSDORF DJ, EVANS RM: The RXR heterodimers and orphan receptors. Cell (1995) 83:841–850.
   PubMed Web of Science ®Google Scholar
• KHURI FR, RIGAS JR, FIGLIN RA et al.:Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2001) 19:2626–2637.
   PubMed Web of Science ®Google Scholar
• BLUMENSCHEIN GR, KHURI FR, GATZEMEIER Y, MILLER WH, VON PAWEL J, RIGAS JR: A randomized Phase III trial comparing bexarotene/ carboplatin/paclitaxel versus carboplatin/ paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. (2005) 23:621 Abstr. 7001.
   Google Scholar
• JASSEM J, ZATLOUKAL P, RAMLAU R, SCHWARZENBERGER P, ORIV S, RODRIGUES-PEREIRA J: A randomized Phase III trial comparing bexarotene/ cisplatin/vinorelbine versus cisplatin/ vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. (2005) 23:Abstr. 7024, 1095.
   Google Scholar
• SALGIA R, SKARIN AT: Molecular abnormalities in lung cancer. J. Clin. OncoL (1998) 16:1207–1217.
   PubMed Web of Science ®Google Scholar
• SANDLER AB, BLUMENSCHEIN GR, HENDERSON T, LEE J, TRUONG M, KIM E: Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2004) 22(145):2000, Abstr.
   Google Scholar
• HUANG S, ARMSTRONG EA, BENAVENTE S, CHINNAIYAN P, HARARI PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. (2004) 64:5355–5362.
   PubMed Web of Science ®Google Scholar
• BONNER JA, GIRALT J, HARARI PM et al.: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a Phase III study of high dose radiation therapy with or without cetuximab. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstr. 5507.
   Google Scholar